Stock Selection - NASDAQ : IMMX
White Glove Trades is a financial newsletter that provides curated stock alerts and stock trading news.
Signing up to join our community is absolutely FREE and there are no commitments required.
We won’t inundate your inbox with emails, we’re simply building a community of like-minded investors and will only reach out with hand picked opportunities curated by our team.
Alert History
Initial Coverage for IMMX began on September 1, 2023
Stock Alert Issued on November 9, 2023
Stock Alert Issued on November 21, 2023
NASDAQ : IMMX
Immix Biopharma (NASDAQ: IMMX) stands proudly at the vanguard of medical innovation, employing avant-garde technology and revolutionary approaches to introduce a groundbreaking concept in the realm of CAR-T therapy – the Outpatient CAR-T Therapy.
This extraordinary advancement aspires to redefine the entire panorama of CAR-T therapy, promising a transformative experience for patients.
IMMX's noble mission is to channel the formidable power of the immune system through innovative cell therapies and other modalities, with the ultimate aim of providing universally accessible cures.
Timeline of Events
FDA APPROVAL OF ODD
The U.S. Food and Drug Administration has granted its distinguished approval of Orphan Drug Designation for Immix Biopharma's NXC-201, recognizing its merit as a treatment for Multiple Myeloma.
Read MoreAugust 23, 2023COVERAGE INITIATED - price $2.29
Our meticulous research and vigilant monitoring of Immix Biopharma (NASDAQ : IMMX) led us to spotlight it as a stellar stock selection on September 1, 2023, at an attractive $2.29 price point.
September 1, 2023Corporate Developements
IMMX continued to bolster its ranks with seasoned advisors, hitting crucial milestones and gaining significant market traction. With the additional Orphan Drug Designation (ODD) for NXC-201 treating Amyloid Light Chain (AL) Amyloidosis, the company's prospects grew even more promising.
Notably, the impressive clinical outcomes in both Multiple Myeloma and Amyloid Light Chain Amyloidosis further solidified our confidence in IMMX's potential.
Read MoreSeptember - October 2023SUBSCRIBER ALERT - PRICE - $3.41
As the stock price retreated from its highs, our expert team swiftly seized the moment, issuing a timely alert on November 9, 2023, at $3.41 per share.
NOVEMBER 9, 2023SUBSCRIBER ALERT - PRICE - $4.17
Subsequently, when IMMX announced another groundbreaking milestone, gaining FDA approval for the IND application of CAR-T NXC-201 for U.S. Patient Dosing, we promptly sent a second alert to our subscribers at $4.17 per share.
Read MoreNOVEMBER 21, 2023About CAR-T Cancer therapy
CAR-T, or Chimeric Antigen Receptor T-cell, therapy stands as a pioneering approach to cancer treatment, wherein the patient's very own immune cells are modified to discern and assail the malignant intruders.
Immix Biopharma (NASDAQ: IMMX) is making noteworthy advancements in the realm of CAR-T cell therapy. Their state-of-the-art CAR-T therapy, named NXC-201, is utilized in the treatment of multiple myeloma and AL amyloidosis, boasting impressive response rates of 95% and 100%, respectively.
In addition, IMMX is actively broadening its portfolio and pursuing FDA approval for NXC-201 through ongoing Phase I/II trials, with the intent to treat 100 patients, of which 63 have already received treatment at the high dosage.
Recent interim data for NXC-201 has been exceedingly promising, positioning it as a potential breakthrough therapy in the formidable battle against these complex diseases.
IMMX’s unwavering commitment to advancing CAR-T technology underscores its dedication to enhancing the lives of patients and provides investors with an opportunity to champion a company at the forefront of pioneering treatments in the biopharmaceutical industry.
Immix Biopharma (NASDAQ: IMMX) has adeptly harnessed cutting-edge technology and innovative approaches to craft a distinctive iteration of CAR-T therapy – the Outpatient CAR-T Therapy. This groundbreaking therapeutic approach marks a reimagination of the entire CAR-T therapy experience.
While the body still receives the fortifying immune cells akin to superheroes, the noteworthy distinction lies in liberating patients from prolonged hospital stays, often spanning weeks or months. The treatment, marked by enhanced convenience and comfort, presents a compelling prospect with indications pointing towards a significantly diminished risk of severe side effects, including neurotoxicity.
This transformative model allows patients to undergo treatment with a heightened sense of peace of mind.
5 Compelling Reasons to Observe IMMX
Innovative CAR-T Therapy
IMMX’s subsidiary, Nexcella, exhibits commendable advancements in the realm of CAR-T cell therapy through its notable NXC-201 treatment. This groundbreaking therapy has demonstrated remarkable response rates, particularly in addressing the complexities of multiple myeloma and AL amyloidosis. Such pioneering endeavors firmly position IMMX as a prospective trailblazer in the realm of cutting-edge biopharmaceuticals.
Clinical Advancements
IMMX is presently engrossed in the active progression of Phase I/II clinical trials for NXC-201, with a strategic initiative to extend treatment to a noteworthy cohort of 100 patients, of which 63 have already undergone treatment at the elevated dosage. Recent interim data augurs exceptionally well, portraying a highly promising trajectory for the therapy and its potential effectiveness in combatting formidable diseases.
Diversified Portfolio
IMMX, with a dedicated commitment to diversification and growth within the biotech sector, is extending its portfolio into the realm of CAR-T cell therapy through Nexcella. This strategic move underscores the company’s proactive stance in embracing innovative avenues, solidifying its position as a dynamic player in the ever-evolving landscape of biotechnology.
Market Position
IMMX maintains a robust foothold in the realm of biotechnology, boasting a commendable market capitalization of approximately $75 million. This notable standing suggests a substantial upside potential in comparison to its industry counterparts. The company’s strategic emphasis on CAR-T technology emerges as a key driver, poised to propel future growth and augment its market capitalization in the evolving landscape of biotechnological endeavors.
Advantage Over Peers
In contrast to its industry counterparts, IMMX distinguishes itself through a steadfast commitment to cutting-edge CAR-T therapy. The company’s unwavering focus on advanced biopharmaceuticals renders it an appealing investment option for discerning individuals seeking innovation and the prospect of substantial growth within the dynamic landscape of the healthcare sector. future growth and augment its market capitalization in the evolving landscape of biotechnological endeavors.
NOTEWORTY News
December 11, 2023
100% (10/10) overall response rate (ORR) and 70% (7/10) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 6 line…
November 21, 2023
NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance72 patients previously dosed with NXC-201 ex-U.S.First CAR-T program for light-chain…
This corporate profile is a not a paid advertisement and is provided for information purposes only; it should not be used as the basis for any investment decision. Barber & Casper, L.L.C., has not been compensated for preparation and distribution of this corporate profile as well as other marketing and investor relations services.
Barber & Casper, L.L.C., and its principals currently hold no shares in the company profiled. Barber & Casper, L.L.C., or its principals may buy or sell securities in the company profiled at any time without notice.
